Why the DOJ’s lawsuit against the UGH-Amedisys merger may not go anywhere

Why the DOJ’s lawsuit against the UGH-Amedisys merger may not go anywhere 
MedCityNews; by Marissa Plescia; 11/21/24 
Experts aren’t sure what the outcome of the DOJ’s recent lawsuit against the proposed UnitedHealth Group/Amedisys merger will be under the incoming Trump administration. The Biden administration has focused more on supporting clinicians, while the previous Trump administration favored corporations. ...  But even aside from the differences in governing philosophy, one expert noted that the main reason for antitrust lawsuits — prices would rise as a result of the transaction, hurting consumers and patients — seems to be missing from the equation here. That’s because of the outsized role Medicare and Medicaid play in the home health industry. ... By acquiring Amedisys, UHG would grow its home health and hospice footprint to five more states, as well as receive 500 additional locations across 32 states it already operates in. The deal would also give UHG control of at least 30% of the home health or hospice services in eight states. ... Will the DOJ succeed? It's hard to say for sure what the outcome of the DOJ’s lawsuit will be, particularly with the change in administration. ...